Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp

Mackenzie Financial Corp lifted its stake in Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) by 487.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 187,559 shares of the company's stock after acquiring an additional 155,656 shares during the quarter. Mackenzie Financial Corp owned approximately 0.34% of Spero Therapeutics worth $193,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of SPRO. Monimus Capital Management LP acquired a new position in Spero Therapeutics in the 4th quarter worth about $320,000. Renaissance Technologies LLC grew its stake in shares of Spero Therapeutics by 13.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,105,591 shares of the company's stock valued at $1,139,000 after buying an additional 130,938 shares in the last quarter. Anson Funds Management LP increased its holdings in Spero Therapeutics by 2.4% in the fourth quarter. Anson Funds Management LP now owns 3,839,886 shares of the company's stock worth $3,955,000 after buying an additional 89,436 shares during the last quarter. JPMorgan Chase & Co. raised its position in Spero Therapeutics by 26,011.9% during the fourth quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company's stock valued at $63,000 after acquiring an additional 61,388 shares in the last quarter. Finally, ADAR1 Capital Management LLC raised its position in Spero Therapeutics by 7.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 801,277 shares of the company's stock valued at $825,000 after acquiring an additional 57,818 shares in the last quarter. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

Spero Therapeutics Stock Down 3.8%

SPRO stock opened at $2.56 on Friday. The firm has a 50 day moving average of $0.92 and a two-hundred day moving average of $0.93. Spero Therapeutics, Inc. has a 12 month low of $0.51 and a 12 month high of $2.95. The company has a market capitalization of $143.13 million, a price-to-earnings ratio of 36.58 and a beta of 0.23.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.30. The business had revenue of $5.87 million during the quarter, compared to analyst estimates of $11.00 million. Spero Therapeutics had a net margin of 3.30% and a return on equity of 4.03%. On average, research analysts expect that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.